Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma

A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months a...

Descripción completa

Detalles Bibliográficos
Autores principales: Muraishi, Junichi, Shibata, Michihiko, Honma, Yuichi, Hiura, Masaaki, Abe, Shintaro, Harada, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577071/
https://www.ncbi.nlm.nih.gov/pubmed/28768965
http://dx.doi.org/10.2169/internalmedicine.56.8233
_version_ 1783260276921991168
author Muraishi, Junichi
Shibata, Michihiko
Honma, Yuichi
Hiura, Masaaki
Abe, Shintaro
Harada, Masaru
author_facet Muraishi, Junichi
Shibata, Michihiko
Honma, Yuichi
Hiura, Masaaki
Abe, Shintaro
Harada, Masaru
author_sort Muraishi, Junichi
collection PubMed
description A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided. In addition, anti-HBs became and remained positive at 31 months after chemotherapy. ETV was re-discontinued at 36 months after chemotherapy.
format Online
Article
Text
id pubmed-5577071
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-55770712017-09-01 Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma Muraishi, Junichi Shibata, Michihiko Honma, Yuichi Hiura, Masaaki Abe, Shintaro Harada, Masaru Intern Med Case Report A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided. In addition, anti-HBs became and remained positive at 31 months after chemotherapy. ETV was re-discontinued at 36 months after chemotherapy. The Japanese Society of Internal Medicine 2017-08-01 /pmc/articles/PMC5577071/ /pubmed/28768965 http://dx.doi.org/10.2169/internalmedicine.56.8233 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Muraishi, Junichi
Shibata, Michihiko
Honma, Yuichi
Hiura, Masaaki
Abe, Shintaro
Harada, Masaru
Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
title Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
title_full Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
title_fullStr Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
title_full_unstemmed Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
title_short Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
title_sort reactivation of occult hepatitis b virus infection 27 months after the end of chemotherapy including rituximab for malignant lymphoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577071/
https://www.ncbi.nlm.nih.gov/pubmed/28768965
http://dx.doi.org/10.2169/internalmedicine.56.8233
work_keys_str_mv AT muraishijunichi reactivationofocculthepatitisbvirusinfection27monthsaftertheendofchemotherapyincludingrituximabformalignantlymphoma
AT shibatamichihiko reactivationofocculthepatitisbvirusinfection27monthsaftertheendofchemotherapyincludingrituximabformalignantlymphoma
AT honmayuichi reactivationofocculthepatitisbvirusinfection27monthsaftertheendofchemotherapyincludingrituximabformalignantlymphoma
AT hiuramasaaki reactivationofocculthepatitisbvirusinfection27monthsaftertheendofchemotherapyincludingrituximabformalignantlymphoma
AT abeshintaro reactivationofocculthepatitisbvirusinfection27monthsaftertheendofchemotherapyincludingrituximabformalignantlymphoma
AT haradamasaru reactivationofocculthepatitisbvirusinfection27monthsaftertheendofchemotherapyincludingrituximabformalignantlymphoma

Ejemplares similares